Pharmaceuticals
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Departmen...
2025-05-16 09:00
4978
Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)
SAN FRANCISCO and SUZHOU, China, May 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-05-16 08:00
8501
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 20:07
2171
Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML * A pooled safety and efficacy analysis of two Phase I/II studies ...
2025-05-15 18:09
3106
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 11:30
2853
Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON, May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the ...
2025-05-14 16:00
2554
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
* Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. * The company has received the EOP2 meeting minutes, confirming the primar...
2025-05-14 13:38
3889
GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California
YONGIN, South Korea, May 14, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that its U.S. subsidiary, ABO Holdings, has received FDA approval for its plasma collection center located inCalexico, California. Following the successful U.S. launch of ALYGLO (im...
2025-05-14 13:21
2921
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
- Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. - The company has received the EOP2 meeting minutes, confirming the ...
2025-05-14 12:01
3835
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
* Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo. SING...
2025-05-14 10:30
2784
Novo Holdings Announces Investment in SCHOTT Poonawalla to Accelerate Growth and Innovation in Injectable Drug Packaging
SINGAPORE, May 14, 2025 /PRNewswire/ -- Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla,India's leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and ...
2025-05-14 09:00
3242
iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization
* Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections * Demonstrated its Efficacy and Safety through previous Clinical Trials * Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotech...
2025-05-13 20:00
2432
Rockwell Automation Launches PharmaSuite 12.00 to Accelerate Secure, Scalable Deployments
Latest MES release helps pharmaceutical and biopharmaceutical manufacturers
simplify system management, improve flexibility and speed time-to-value
MILWAUKEE, May 13, 2025 /PRNewswire/ -- Rockwell Automation, Inc.
2025-05-13 19:00
3308
Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain
SHANGHAI, May 13, 2025 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially signed a strategic cooperation agreement. The two companies will integrate their core streng...
2025-05-13 18:00
2804
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
* Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology com...
2025-05-13 17:00
3362
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the 2025 ESMO G...
2025-05-13 11:38
6769
Illuccix China Phase 3 Study Completes Enrolment
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imagi...
2025-05-13 07:22
2762
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting
SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio "), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and...
2025-05-12 20:30
3011
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希® ), the first domestically approved antibody-drug conjugate (ADC...
2025-05-12 16:29
5763
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof.Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research[1], authored b...
2025-05-12 15:44
5352
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 311 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 298 media titles]
2026-08-06 15:10
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 298 media titles]
2026-08-04 07:00
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 294 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
13333
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
11378
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
9815
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
9463